GSK announced on June 9 the acquisition of Nuvalent Bio for $10.6 billion, marking the second-largest takeover in the biopharmaceutical industry so far this year. The agreement will see GSK purchase all outstanding shares of Nuvalent at $124 each, representing a 40% premium over Nuvalent’s last closing price of $88.49.
Truist Securities said, “GSK was not the most anticipated strategic acquirer discussed in our recent investor conversations.” The analysts added that the deal aligns with GSK’s recent pipeline prioritizations and poses “low antitrust risk given limited overlap” between the two companies’ pipelines. Truist also said that the acquisition “crystallizes [Nuvalent’s] full value for a de-risked platform with the premium reflecting the clear regulatory line-of-sight and competitive commercial potential” of Nuvalent’s pipeline.
Nuvalent's lead cancer assets include zidesamtinib, a ROS1 blocker, and neladalkib, an ALK inhibitor. Both drugs are under review by the Food and Drug Administration for non-small cell lung cancer, with approval decisions expected by September 18 and November 27, respectively. These candidates are also being developed for solid tumors in mid-stage trials, according to information on Nuvalent’s website. Truist currently models combined peak revenue of around $3.5 billion for these two drugs.
If approved, GSK plans to launch both drugs this year and believes they have “multi-blockbuster potential,” according to Tuesday’s release. The acquisition will also give GSK access to NVL-330, a HER2 blocker in early-stage trials for non-small cell lung cancer, as well as other undisclosed preclinical precision oncology medicines from Nuvalent.
The transaction is expected to close in the third quarter pending customary conditions. This marks GSK's third significant acquisition this year; earlier deals included RAPT Therapeutics for $2.2 billion focused on food allergies and 35Pharma for $950 million targeting pulmonary hypertension.
In terms of broader industry context, GSK's purchase ranks just behind Sun Pharma's $11.75 billion acquisition of Organon in April as one of this year's largest deals across biopharma.
